An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Ascletis, a drug company, just got the green light from the U.S. Food and Drug Administration (FDA) to start a first-in-human (Phase I) study of a new injectable drug called ASC35. That means regulators have reviewed the basic safety plan and allowed Ascletis to give this experimental medicine to people for the first time in the U.S. The study will test a once-monthly injected version given under the skin for treating obesity. ASC35 is described as a "dual peptide agonist" that acts on two receptors called GLP-1R and GIPR. In plain terms, it’s a lab-made small protein (peptide) that imitates two natural hormones involved in appetite and metabolism. One of those hormones (the GLP-1 system) is what drugs like Ozempic and Wegovy copy to reduce appetite and slow stomach emptying. The other (GIP) is a different hormone that also affects blood sugar and fat handling. By hitting both targets, ASC35 aims to combine benefits of each. The announcement is about regulatory clearance to start Phase I testing, not about results. Phase I studies usually involve a small number of healthy volunteers or people with the condition and focus mainly on safety, how the drug behaves in the body, and the right dosing. We do not yet have human data showing whether ASC35 causes weight loss, how much, or how it compares to existing medicines. The key point is: this is the start of testing in humans, not proof it works. Why this matters is practical: current GLP‑1 drugs require weekly injections and have transformed obesity treatment for many people. A once‑monthly option could be more convenient and might help people stick with treatment better. Also, combining two hormone pathways could potentially improve effectiveness, though that’s an open question. Patients, doctors, and investors will watch these early trials to see if ASC35 is safe, tolerable, and shows signs of the weight-loss effects people want. There are important caveats. Phase I trials are small and not designed to prove effectiveness. Potential side effects for drugs in this family can include nausea, vomiting, diarrhea, and rare but serious risks that need larger studies to detect. We don’t yet know long-term safety, whether the once-monthly formulation works as hoped, or how it will compare to approved drugs. FDA clearance to start a study is a routine regulatory step and not an endorsement of effectiveness. Bottom line: Ascletis has permission to begin human testing of ASC35, a once‑monthly dual-hormone peptide shot for obesity—an early but necessary step that raises possibilities, not promises.
Source: PR Newswire